Your browser doesn't support javascript.
loading
Expression of pro- and anti-inflammatory cytokines during anti-proprotein convertase subtilisin/kexin type 9 therapy in patients with statin-resistant familial hypercholesterolemia.
Morales-Portano, Julieta Danira; Trujillo-Cortés, Rafael; Roa-Martínez, Bricia Margarita; Pérez-Cabeza de Vaca, Rebeca; García, Silvia; Mondragón-Terán, Paul; Suárez-Cuenca, Juan A.
Afiliación
  • Morales-Portano JD; Cardiology Department, National Medical Center "20 de Noviembre," ISSSTE, Mexico City, Mexico.
  • Trujillo-Cortés R; Cardiology Department, National Medical Center "20 de Noviembre," ISSSTE, Mexico City, Mexico.
  • Roa-Martínez BM; Cardiology Department, National Medical Center "20 de Noviembre," ISSSTE, Mexico City, Mexico.
  • Pérez-Cabeza de Vaca R; Coordination of Research, National Medical Center "20 de Noviembre," ISSSTE, Mexico City, Mexico.
  • García S; Clinical Research Department, National Medical Center "20 de Noviembre," ISSSTE, Mexico City, Mexico.
  • Mondragón-Terán P; Coordination of Research, National Medical Center "20 de Noviembre," ISSSTE, Mexico City, Mexico.
  • Suárez-Cuenca JA; Cardiology Department, National Medical Center "20 de Noviembre," ISSSTE, Mexico City, Mexico.
Front Cardiovasc Med ; 11: 1417044, 2024.
Article en En | MEDLINE | ID: mdl-39091354
ABSTRACT

Background:

Some clinical dyslipidemia cases do not respond to statins, known as statin-resistant familial hypercholesterolemia (SR-FH), in which patients are under a high cardiovascular risk despite statin therapy. Therefore, novel therapeutic alternatives are required. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce cholesterol levels and cardiovascular disease risk, particularly in patients with SR-FH, where PCSK9i may differentially affect pro- and anti-inflammatory mediators depending on the clinical setting.

Aim:

To evaluate the effect of PCSK9i treatment on pro- and anti-inflammatory cytokines in patients with SR-FH.

Methods:

Before-after comparison, quasi-experimental, single-center study in patients with SR-FH. Blood samples were processed to obtain complete blood counts of glycated hemoglobin and serum lipid levels. Flow cytometry was performed to characterize baseline circulating M1- and M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, interleukins (ILs), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF)-alpha. The endpoints were lower serum lipid levels and pro-inflammatory mediator modification.

Results:

Twenty patients with SR-FH, aged 58 years and most of them males, were included, with a mean body-mass index of 26.4 and showing ischemic heart disease and similar values of baseline M1- and M2-macrophages and monocytes. Six-month iPSCK-9 therapy considerably reduced LDLc, increased anti-inflammatory cytokine (IL-4), and modified pro-inflammatory cytokine (TNF-alpha and MCP-1) levels. No notable effects were observed for the other markers.

Conclusion:

PCSK9i therapy exerted subclinical anti-inflammatory and anti-atherogenic effects, indicating potential benefits for clinical outcomes.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Cardiovasc Med Año: 2024 Tipo del documento: Article País de afiliación: México Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Cardiovasc Med Año: 2024 Tipo del documento: Article País de afiliación: México Pais de publicación: Suiza